HER-2 amplification in tubular carcinoma of the breast

American Journal of Clinical Pathology

Volumn 126, Issue 1, 2006, Pages 55-58

  Oakley III, Gerard J ^a   Tubbs, Raymond R ^b   Crowe, Joseph ^b   Sebek, Bruce ^b   Budd, G Thomas ^b   Patrick, Rebecca J ^b   Procop, Gary W ^b,c  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; HER 2 amplification; Tubular carcinoma

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER INVASION; CARCINOMA IN SITU; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

EID: 33745803196     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/E0YEKHBP3YYQYUBD     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts & Figures 2000. Baltimore, MD: Williams & Wilkins; 2000.
2. Tandon AK, Clark GM, Chamness GC, et al. HER2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120-1128.
3. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359-377.
4. Rilke F, Colnaghi Ml, Cascinelli N, et al. Prognostic significance of HER2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
6. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
7. Scawn R, Shousha S. Morphologic spectrum of estrogen receptor-negative breast carcinoma. Arch Pathol Lab Med. 2002;126:325-330.
8. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239-1245.
9. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer. 1990;65:1794-1800.
10. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol. 1992;45:16-20.
11. Soomro S, Shousha S, Taylor P, et al. c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol. 1991;44:211-214.
12. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916-921.
13. Page DL, Anderson T. Diagnostic Histopathology of the Breast. New York, NY: Churchill Livingstone; 1987:211-215.
14. O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol. 2003;30(2 suppl 3):22-26.
15. Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment. Expert Rev Anticancer Ther. 2003;3:403-408.
16. Jahanzeb M. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. Clin Breast Cancer. 2003;4:28-38.
17. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48:1238-1243.
18. Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2003;79:187-198.
19. Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer. 2002;95:2068-2075.
20. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995;75:1320-1326.
21. Cline MJ, Battifora H, Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol. 1987;5:999-1006.